Recent Company News

• 02:35 AM ET May 18, 2026
  

  Japan's MHLW approves Chugai's Alecensa for advanced or recurrent ALK fusion gene-positive solid tumors including pediatric patients (¥7885.0000, 0)

• 02:34 AM ET May 18, 2026
  

  Japan's MHLW approves Chugai's FoundationOne CDx Cancer Genomic Profile as companion diagnostic for Alecensa for ALK fusion gene-positive solid tumors (¥7885.0000, 0)

• 06:46 PM ET May 12, 2026
  

  Eli Lilly reports Surmount-maintain and Attain-maintain late-phase trials results, people with obesity maintained weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy ($989.87, 0.00)

• 03:35 PM ET May 02, 2026
  

  Biomarin Pharmaceutical presents new data on the effect of long-term treatment with VOXZOGO (vosoritide) on arm span, bone health and growth in children with achondroplasia at PES 2026 ($54.06, 0.00)

• 11:25 PM ET Apr 26, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:03 PM ET Apr 26, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 06:00 AM ET Apr 24, 2026
  

  Transcript Intelligence: Chugai Pharmaceutical Q1 Earnings Guidance

• 06:00 AM ET Apr 24, 2026
  

  Transcript Intelligence: Chugai Pharmaceutical Q1 Earnings Q&A